Long-term outcomes of electrocoagulation versus radiofrequency thermoablation for varicose veins
Journal of Vascular Surgery: Venous and Lymphatic Disorders · 2025
DOI: 10.1016/j.jvsv.2025.102245 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2025. Verfasst von Fábio Henrique Rossi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Dante Pazzanese Cardiovascular Institute, São Paulo, Brazil. Electronic address: vascular369@hotmail.com. Hauptthemen laut MEDLINE: Varicose Veins, Saphenous Vein, Electrocoagulation, Radiofrequency Ablation. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
OBJECTIVE: Thermoablation is increasingly being used as an alternative to traditional surgery for treating primary varicose veins. Electrocoagulation ablation (EA) of the great saphenous vein (GSV) has demonstrated effectiveness and safety comparable with that of radiofrequency ablation (RFA); however, its long-term outcomes have not been investigated previously. METHODS: This study involves a long-term follow-up of patients who participated in a double-blind, randomized clinical trial. Individuals with lower limb varicose veins and incompetence of GSV were randomly assigned to two treatment groups: EA and RFA. Follow-up assessments were scheduled at 1 week, 3 months, 6 months, and annually thereafter. The primary outcome measured was GSV occlusion, evaluated through postoperative duplex ultrasound examination. Secondary outcomes included the complication rate and improvements in quality of life, assessed using the Aberdeen Varicose Vein Questionnaire score. RESULTS: A total of 57 patients were included, which involved a cumulative 85 treated GSVs; 42 veins were treated with EA and 43 with RFA. At the 1-week, 3-month, and 6-month follow-ups, there were no statistically significant differences between the two groups regarding GSV occlusion rates (P = .430, P = .157, and P = .157, respectively), complication rates (P = .717, P = .317, and P = .320, respectively), or improvements in quality-of-life scores (P = .540, P = .786, and P = .401, respectively). After a median follow-up duration of 4.8 years (95% confidence interval, 4.5-5.1 years), data for 59 procedures (69.4%) were available, showing occlusion rates of 89.7% for the EA group (n = 29) and 66.7% for the RFA group (n = 30) (P = .001). There were no procedure-related complications (P = .127) and no significant differences in the Aberdeen Varicose Vein Questionnaire scores (P = .345) between the two groups analyzed. CONCLUSIONS: EA has demonstrated effectiveness and safety for ablation of the GSV, achieving a higher rate of venous occlusion compared with RFA in the long-term follow-up. Additionally, the occurrence of complications and the impact on symptoms and quality of life were comparable between the two methods during long-term follow-up.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Dante Pazzanese Cardiovascular Institute, São Paulo, Brazil. Electronic address: vascular369@hotmail.com.
- Dante Pazzanese Cardiovascular Institute, São Paulo, Brazil.
Zitieren
APA
Rossi, F. H., Beteli, C. B., & Tannus, M. M. (2025). Long-term outcomes of electrocoagulation versus radiofrequency thermoablation for varicose veins. Journal of Vascular Surgery: Venous and Lymphatic Disorders. https://doi.org/10.1016/j.jvsv.2025.102245
Vancouver
Rossi FH, Beteli CB, Tannus MM. Long-term outcomes of electrocoagulation versus radiofrequency thermoablation for varicose veins. Journal of Vascular Surgery: Venous and Lymphatic Disorders. 2025. doi:10.1016/j.jvsv.2025.102245
BibTeX
@article{Rossi2025,
author = {Rossi, Fábio Henrique and Beteli, Camila Baumann and Tannus, Miguel Monteiro},
title = {Long-term outcomes of electrocoagulation versus radiofrequency thermoablation for varicose veins},
journal = {Journal of Vascular Surgery: Venous and Lymphatic Disorders},
year = {2025},
doi = {10.1016/j.jvsv.2025.102245}
}
EUVIMED